Sanofi and Regeneron Strike $7 Billion Deal for New Treatments
French drugmaker Sanofi has entered into a $7 billion agreement with Regeneron to develop new treatments. This strategic move aims to replenish Sanofi's drug pipeline as a key existing drug approaches patent expiry. The company's new CEO possesses the financial capacity to pursue further acquisitions.
By Aimee DonnellanThe $100 bln French drugmaker struck a $7 bln deal with Regeneron to develop new treatments. Restocking its pipeline makes sense as a key drug faces patent expiry, but given the scale of the problem, more deals will follow. Full view…